As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.